참고문헌
- Attia J, Thakkinstian A, D'Este C (2003). Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol, 56, 297-303. https://doi.org/10.1016/S0895-4356(03)00011-8
- Aung PP, Matsumura S, Kuraoka K, et al (2005). No evidence of correlation between the single nucleotide polymorphism of DNMT3B promoter and gastric cancer risk in a Japanese population. Oncol Rep, 14, 1151-4.
- Bao Q, He B, Pan Y, et al (2011). Genetic variation in the promoter of DNMT3B is associated with the risk of colorectal cancer. Int J Colorectal Dis, 9, 1107-12.
- Fan H, Zhang F, Hu J, et al (2008). Promoter polymorphisms of DNMT3B and the risk of colorectal cancer in Chinese: a case-control study. J Exp Clin Cancer Res, 27, 24. https://doi.org/10.1186/1756-9966-27-24
- He M, Fan J, Jiang R, et al (2013). Expression of DNMTs and genomic DNA methylation in gastric signet ring cell carcinoma. Mol Med Rep, 8, 942-8. https://doi.org/10.3892/mmr.2013.1566
- Hermann A, Gowher H, Jeltsch A (2004). Biochemistry and biology of mammalian DNA methyltransferases. Cell Mol Life Sci, 61, 2571-87. https://doi.org/10.1007/s00018-004-4201-1
- Hu J, Fan H, Liu D, Zhang S, Zhang F, Xu H (2010) DNMT3B promoter polymorphism and risk of gastric cancer. Dig Dis Sci, 55, 1011-6. https://doi.org/10.1007/s10620-009-0831-3
-
Iacopetta B, Heyworth J, Girschik J, et al (2009). The MTHFR C677T and
${\Delta}$ DNMT3B C -149T polymorphisms confer different risks for right and left-sided colorectal cancer. Int J Cancer, 125, 84-90. https://doi.org/10.1002/ijc.24324 - Jones JS, Amos CI, Pande M, et al (2006). DNMT3b polymorphism and hereditary nonpolyposis colorectal cancer age of onset. Cancer Epidemiol Biomarkers Prev, 15, 886-91. https://doi.org/10.1158/1055-9965.EPI-05-0644
- Jin B, Robertson KD (2013). DNA methyltransferases, DNA damage repair, and cancer. Adv Exp Med Biol, 754, 3-29.
- Karpinski P, Myszka A, Ramsey D, et al (2010). Polymorphisms in methyl-group metabolism genes and risk of sporadic colorectal cancer with relation to the CpG island methylator phenotype. Cancer Epidemiol, 34, 338-44. https://doi.org/10.1016/j.canep.2010.03.002
- Karpinski P, Myszka A, Ramsey D, et al (2009). Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG Island hypermethylation in colorectal cancer. Cancer Epidemiol Biomarkers Prev, 18, 3086-96. https://doi.org/10.1158/1055-9965.EPI-09-0289
- Naghibalhossaini F, Mokarram P, Khalili E, et al (2015). DNMT3b -149C/T promoter variants and methylation of colorectal cancer-associated genes. Cancer Biomark, 15, 227-33. https://doi.org/10.3233/CBM-150463
- Pavlopoulou A, Kossida S (2010). Cytosine methyltransferases as tumor markers. Curr Genomics, 11, 568-77. https://doi.org/10.2174/138920210793360916
-
Reeves D, Mossman CJ, Meldrum G, et al (2008). The -149C>T SNP within the
${\Delta}$ DNMT3B gene, is not associated with early disease onset in hereditary non-polyposis colorectal cancer. Cancer Lett, 265, 39-44. https://doi.org/10.1016/j.canlet.2008.02.005 - Vizoso M, Puig M, Carmona FJ, et al (2015). Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts. Carcinogenesis, 36, 1453-63.
- Wang C, Jia Z, Cao D, et al (2015). Polymorphism of DNA Methyltransferase 3b and Association with Development and Prognosis in Gastric Cancer. PLoS One, 10, 134059.
- Wang YM, Wang R, Wen DG, et al (2005). Single nucleotide polymorphism in DNA methyltransferase 3B promoter and its association with gastric cardiac adenocarcinoma in North China. World J Gastroenterol, 11, 3623-7. https://doi.org/10.3748/wjg.v11.i23.3623
- Xia Z, Duan F, Jing C, et al (2015). Quantitative assessment of the association between DNMT3B-579G>T polymorphism and cancer risk. Cancer Biomark, 15, 707-16. https://doi.org/10.3233/CBM-150512
- Zhu J, Du S, Zhang J, et al (2015). Polymorphism of DNA methyltransferase 3B -149C/T and cancer risk: a metaanalysis. Med Oncol, 32, 399. https://doi.org/10.1007/s12032-014-0399-4
- Zhang Y, Xu H, Shen Y, et al (2015). Association of DNMT3B -283 T > C and -579 G > T polymorphisms with decreased cancer risk: evidence from a meta-analysis. Int J Clin Exp Med, 8, 13028-38.